MAPK-IN-2

MAPK-IN-2 is a potent multi-kinase inhibitor targeting key oncogenic drivers including EGFR, B-RAF, c-MET, and CDK4/6. It demonstrates strong anti-proliferative activity in vitro against various cancer cell lines, particularly those harboring EGFR T790M and B-RAF V600E mutations, making it a valuable tool for cancer signaling pathway research.